PMID- 35440002
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 1750-9378 (Print)
IS  - 1750-9378 (Electronic)
IS  - 1750-9378 (Linking)
VI  - 17
IP  - 1
DP  - 2022 Apr 19
TI  - Rat bone marrow mesenchymal stem cells (BMSCs) inhibit liver fibrosis by 
      activating GSK3beta and inhibiting the Wnt3a/beta-catenin pathway.
PG  - 17
LID - 10.1186/s13027-022-00432-4 [doi]
LID - 17
AB  - BACKGROUND: Bone marrow mesenchymal stem cells (BMSCs) can effectively alleviate 
      liver fibrosis, which is a pathological injury caused by various chronic liver 
      diseases. This study aimed to investigate the antifibrotic effects of BMSCs and 
      elucidate the underlying mechanism by which BMSCs affect liver fibrosis in vitro 
      and in vivo. METHODS: After the rat liver fibrosis model was induced by 
      continuous injection of carbon tetrachloride (CCl(4)), BMSCs were administered 
      for 4 weeks, and histopathological analysis and liver function tests were 
      performed. T6 hepatic stellate cells (HSC-T6 cells) were stimulated by TGF-beta1, 
      and the activation and proliferation of cells were analyzed by CCK-8 assays, flow 
      cytometry, real-time PCR, western blotting and enzyme-linked immunosorbent assay 
      (ELISA). RESULTS: Our data demonstrated that BMSCs effectively reduced the 
      accumulation of collagen, enhanced liver functionality and ameliorated liver 
      fibrosis in vivo. BMSCs increased the sub-G1 population in HSC-T6 cells. In 
      addition, coculture with BMSCs reduced the expression of alpha-SMA, collagen I, 
      cyclin-D1, and c-Myc in HSC-T6 cells and activated the phosphorylation of GSK3beta. 
      The GSK3beta inhibitor SB216763 reversed the effect of BMSCs. The Wnt/beta-catenin 
      signalling pathway was involved in BMSC-mediated inhibition of HSC-T6 cell 
      activation. CONCLUSIONS: Our data suggested that BMSCs exerted antifibrotic 
      effects by activating the expression of GSK3beta and inhibiting the Wnt3a/beta-catenin 
      signalling pathway.
CI  - (c) 2022. The Author(s).
FAU - Liu, Zhaoguo
AU  - Liu Z
AD  - The Second School of Clinical Medicine, Southern Medical University, Guangzhou, 
      Guangdong Province, China.
AD  - Liuzhou Worker's Hospital, Liuzhou, Guangxi Province, China.
FAU - Zhou, Song
AU  - Zhou S
AD  - The Second School of Clinical Medicine, Southern Medical University, Guangzhou, 
      Guangdong Province, China.
FAU - Zhang, Ya
AU  - Zhang Y
AD  - The Second School of Clinical Medicine, Southern Medical University, Guangzhou, 
      Guangdong Province, China.
FAU - Zhao, Ming
AU  - Zhao M
AD  - The Second School of Clinical Medicine, Southern Medical University, Guangzhou, 
      Guangdong Province, China. zhaoming02@hotmail.com.
AD  - Department of Organ Transplantation, The Second School of Clinical Medicine, 
      Southern Medical University, Guangzhou, 510280, Guangdong Province, China. 
      zhaoming02@hotmail.com.
LA  - eng
PT  - Journal Article
DEP - 20220419
PL  - England
TA  - Infect Agent Cancer
JT  - Infectious agents and cancer
JID - 101276559
PMC - PMC9017036
OTO - NOTNLM
OT  - BMSCs
OT  - GSK3beta
OT  - Hepatic stellate cells
OT  - Liver fibrosis
OT  - Wnt/beta-catenin pathway
COIS- The authors declare that they have no competing interests.
EDAT- 2022/04/21 06:00
MHDA- 2022/04/21 06:01
PMCR- 2022/04/19
CRDT- 2022/04/20 05:08
PHST- 2022/02/24 00:00 [received]
PHST- 2022/04/11 00:00 [accepted]
PHST- 2022/04/20 05:08 [entrez]
PHST- 2022/04/21 06:00 [pubmed]
PHST- 2022/04/21 06:01 [medline]
PHST- 2022/04/19 00:00 [pmc-release]
AID - 10.1186/s13027-022-00432-4 [pii]
AID - 432 [pii]
AID - 10.1186/s13027-022-00432-4 [doi]
PST - epublish
SO  - Infect Agent Cancer. 2022 Apr 19;17(1):17. doi: 10.1186/s13027-022-00432-4.